CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BI 706321Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2411 Relaxation Therapy Wiki 1.00
drug696 Cognitive Behavioral Therapy Wiki 0.71
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D001010 Anxiety, Separation NIH 0.71
D000072861 Phobia, Social NIH 0.71
D000379 Agoraphobia NIH 0.71
D010698 Phobic Disorders NIH 0.71
D016584 Panic Disorder NIH 0.58
D004194 Disease NIH 0.17
D001008 Anxiety Disorders NIH 0.15

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0000756 Agoraphobia HPO 0.71

There is one clinical trial.

Clinical Trials

1 Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 706321 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)

The main objectives are: - Part I: To investigate safety, tolerability, and pharmacokinetics (PK) of BI 706321 in healthy male subjects following oral administration of single rising doses. - Part II: The relative bioavailability of BI 706321 after administration of tablets and capsules under fasted conditions will be compared with each other and the effect of food on the tablet bioavailability will be investigated.

NCT03971695 Healthy Drug: BI 706321 Drug: Placebo

Primary Outcomes

Measure: Part I: Safety and tolerability of BI 706321 is the percentage of subjects with drug-related adverse events

Time: Up to 22 Days

Measure: Part II: AUC0-tz (area under the concentration-time curve of BI 706321 in plasma over the time interval from 0 to the last quantifiable data point)

Time: Up to 22 Days

Measure: Part II: Cmax (maximum measured concentration of BI 706321 in plasma)

Time: Up to 22 Days

Secondary Outcomes

Measure: Part I: AUC0-∞ (area under the concentration-time curve of BI 706321 in plasma over the time interval from 0 extrapolated to infinity)

Time: Up to 22 Days

Measure: Part I: Cmax (maximum measured concentration of BI 706321 in plasma)

Time: Up to 22 Days

Measure: Part I: tmax (time from dosing to the maximum measured concentration of BI 706321 in plasma)

Time: Up to 22 Days

Measure: Part II: AUC0-∞ (area under the concentration-time curve of BI 706321 in plasma over the time interval from 0 extrapolated to infinity)

Time: Up to 22 Days

No related HPO nodes (Using clinical trials)